Linagliptin Catalog No.:M10654-10 RVX-208 was used at 10

RVX-208 was used at 10 μM final concentration in various in vitro assays

Solubility: DMSO: 56 mg/mL(201

Villagomez R

Smiles: CC1=NC(=C(C=C1C(=O)OCC)C#N)N1CCC(CC1)C(=O)NS(=O)(=O)CC1C=CC=CC=1

3-dihydro-1H-indole-5-sulfonamide

Linagliptin Catalog No.:M10654-10 RVX-208 was used at 10Linagliptin, also known as BI 1356, is a DPP 4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes. Linagliptin (once daily) was approved by the US FDA on 2 May 2011 for treatment of type II diabetes. It is being marketed by Boehringer Ingelheim and Lilly. Product information CAS Number: 668270 12 0 Molecular Weight: 472. 54 Formula: C25H28N8O2 Chemical Name: 8 [(3R) 3 aminopiperidin 1 yl] 7 (but 2 yn 1 yl) 3 methyl 1 [(4